Lynch M G, Whitson J T, Brown R H, Nguyen H, Drake M M
Department of Ophthalmology, University of Texas Southwestern Medical Center, Dallas.
Arch Ophthalmol. 1988 Jul;106(7):908-11. doi: 10.1001/archopht.1988.01060140054023.
Topical beta-blocking agents have been associated with adverse central nervous system (CNS) effects, including depression, emotional lability, and sexual dysfunction. Two studies were done to determine if patients who develop CNS effects while using timolol maleate would improve with betaxolol hydrochloride. In one study, 18 patients with CNS symptoms during timolol therapy were switched to betaxolol. Sixteen of the 18 patients noted symptomatic improvement with betaxolol. The second study involved seven patients with CNS symptoms during timolol therapy who were entered into a double-masked cross-over study. In two patients CNS symptoms resolved with betaxolol; in three patients symptoms improved; and in one patient symptoms worsened with betaxolol. Although factors influencing beta-blocker activity in the CNS are not well understood, there may be some advantage to a selective agent.
局部用β受体阻滞剂与不良中枢神经系统（CNS）效应相关，包括抑郁、情绪不稳定和性功能障碍。开展了两项研究，以确定使用马来酸噻吗洛尔时出现CNS效应的患者改用盐酸倍他洛尔后症状是否会改善。在一项研究中，18例在噻吗洛尔治疗期间出现CNS症状的患者改用了倍他洛尔。18例患者中有16例表示使用倍他洛尔后症状改善。第二项研究纳入了7例在噻吗洛尔治疗期间出现CNS症状的患者，进行双盲交叉研究。2例患者使用倍他洛尔后CNS症状消失；3例患者症状改善；1例患者使用倍他洛尔后症状恶化。尽管影响β受体阻滞剂在中枢神经系统中活性的因素尚未完全明确，但选择性药物可能具有一定优势。
